AMPK/Nrf2 signaling in RAW 264.7 macrophages
Cell-based study · Murine RAW 264.7 macrophage cell line [1]
Isoliquiritigenin increased ARE reporter activity, nuclear Nrf2 and antioxidant-enzyme expression. Compound C attenuated AMPK phosphorylation and nuclear Nrf2, supporting pathway involvement without proving a direct molecular target.
| Endpoint | Reported result | Reference |
|---|---|---|
| ARE reporter activity and Nrf2 nuclear accumulation | direction Increased | [1] |
| ISL-induced AMPK phosphorylation and nuclear Nrf2 with compound C | direction Attenuated by compound C | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 5, 10, 20 µM for reporter concentration series; 20 µM for time courses
- Exposure duration
- Reporter: 18 h concentration series or 1, 3, 6, 18 h; Nrf2 blots: 1, 3, 6 h; enzyme blots: 1, 3, 6, 18 h; AMPK blots: 0.5, 1, 3 h
- Method
- Cell treatment; dual-luciferase ARE reporter and immunoblotting
- Co-treatment
- Compound C 5 µM for 24 h followed by ISL for 3 h in Figure 2F; not part of ISL-only series.
- Reported limits
- Solvent and final vehicle concentration are not specified for Figure 2. Caption reports n = 5 without defining independent biological repeats.
Methods and source locations
Compound reported in the paper: Isoliquiritigenin; Compound label in the paper: ISL
Research findings for the tested material; does not validate an Adooq lot or establish clinical efficacy.
S2-1–S2-4, S2-15–S2-17; S3-2; Figure 2A–F
ARE reporter activity and Nrf2 nuclear accumulation: Dual-luciferase reporter; Nrf2 blots with β-actin and Lamin B controls; mean ± SEM, n = 5 as captioned. — Figure 2A–D; S3-2
ISL-induced AMPK phosphorylation and nuclear Nrf2 with compound C: Immunoblots; control, ISL, compound C, combination; mean ± SEM, n = 5 as captioned. Pharmacological inhibition does not establish inhibitor specificity. — Figure 2E–F; S3-2